ARGX Stock argenx SE
US · NasdaqGSLast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
Overdone October selloff creates an attractive entry into a rapidly expanding immunology franchise.
Future value: $1,149.65 (+32.19%) · 6-12 months · analyst consensus
Signal breakdown
- ▸RBC reiterated Outperform after selloff, citing revenue and pipeline growth.
- ▾Below 50-day MA (-8.66%)
- ▸Above 200-day MA — long-term uptrend
- ▸Volume 1.6× average — accumulation
- ▸~32% upside to price target
Is ARGX a buy right now?
Trend: ARGX is trading below the 50-day average (-8.81%), RSI 38 — neutral momentum, with a 3-month return of -0.33%.
Valuation & quality: argenx SE trades on a trailing P/E of 30.1, forward P/E 26.1, PEG 1.02, price-to-book 161.48; fundamentals show net margin 31.7%, revenue growth 52.1% year on year.
Analyst consensus: 23 analysts have a mean 12-month price target of $1150.35 (+32.3% vs the last close; range $861.00 – $1353.00), consensus rating “buy”.
Our screen: STRONG BUY (score 5) — Overdone October selloff creates an attractive entry into a rapidly expanding immunology franchise.
Computed from end-of-day data; not personal advice.
Our track record with ARGX
First flagged in our daily picks as STRONG BUY on 2026-10-21 at $869.72 — +0% since.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -4.80% | +7.00% | +6.90% | +11.00% | -8.00% | +20.80% | -7.10% | -9.30% |
Fundamentals
Analyst price target
Technical signals
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Sector: Healthcare · Industry: Biotechnology · Netherlands · 1,863 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.